Navigation Links
Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
Date:11/30/2011

CLEVELAND, Nov. 30, 2011 /PRNewswire/ -- University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance…just not as they originally thought.

The "LateTIME" trial was a study of adult stem cells (autologous) harnessed from bone marrow that were believed to have the ability to improve heart function after an attack if injected into the heart within two weeks of the attack.

Results were released this week at the 2011 American Heart Association (AHA) Scientific Sessions conference and were subsequently published this week in Journal of the American Medical Association (JAMA). The results have shown the injections within that timeframe were not favorable, but the concept showed great promise, according to an accompanying JAMA editorial that assessed the trial.

Despite the initial low return, the therapy had effectiveness for some of the patients that were enrolled in the trial as demonstrated by improved heart function post stem cell injection.

Both UH Case Medical Center's Drs. Dan Simon and Marco Costa, co-investigators in the LateTIME study, are currently participating in a similar trial, "TIME" that already has reduced the time between attack and stem cell injection.

The pair is optimistic the time variable adjustment in the new trial will lend favorable outcomes.

"We have reason to believe, as supported by data, that an adjusted injection timeframe could yield stronger results and support for stem cell injections rebuilding damaged heart muscle and function," said Dr. Simon, Chief, Cardiovascular Medicine at UH Case Medical Center and the Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve University School of Medicine.

"The results were not positive, but if you put it into perspective, the foundation or blueprint for success was discovered and that could certainly lead to advanced treatment options for these patients," said Dr. Costa, Director of the Interventional Cardiovascular Center and Research & Innovation Center at UH Case Medical Center as well as a Professor of Medicine at Case Western Reserve University School of Medicine.

The shared theories in both trials is that the specialized cells could have the ability to promote blood vessel growth, prevent cell death and transform themselves into a number of tissues, including muscle. After an acute heart attack, a remodeling process was initiated in the heart in an attempt to compensate for the damaged areas.

Researchers surmised that the condition of the heart muscle several weeks after the attack may differ considerably from the heart muscle in the acute stage setting. For some patients delaying the delivery of stem cells by two to three weeks may have been better than initiating the treatment during the acute phase. 

All patients underwent baseline assessments that included medical history, physical exam, electrocardiogram, blood draws, echocardiogram and MRI tests. Participants were then assigned randomly to receive the stem cells or placebo within the aforementioned two to three week timeline.

The morning of stem cell or placebo infusion, a blood draw and bone marrow aspiration procedure of the hip bone are conducted to collect the stem cells. Later the same day, either stem cells or placebo are then infused through a catheter and directly into the damaged area of the heart.

Following the first 24 hours of the infusion, participants wear a small ECG machine, or Holter monitor. Additionally, patients record their body temperature twice a day for 30 days post infusion. Follow up visits at months one, three, six, 12 and 24 where baseline assessment testing are conducted.

The TIME trial adjusts that variable and results will be published in two years.


'/>"/>
SOURCE University Hospitals Case Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
3. CU-Boulder python study may have implications for human heart health
4. New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network
5. HeartWare Schedules Third Quarter Conference Call and Webcast
6. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
7. HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient
8. Total Artificial Heart Patient Enjoys Spotlight as "The Only Man in Turkey Who Lives Without a Heart"
9. HeartWare to Present at the UBS Global Life Sciences Conference
10. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
11. 1st Pediatric Total Artificial Heart Patient Discharged Home Using Freedom® Portable Driver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... -- Good Start Genetics, a leading family genomics company, ... covered lives mark through its most recent payor addition, ... . With newly signed contracts nationally and others in ... acceptance based on the quality of its science, the ... industry-leading customer care and support and its published cost-effectiveness ...
Breaking Biology Technology:
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
Breaking Biology News(10 mins):